Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:232840.
doi: 10.1155/2011/232840. Epub 2011 Aug 14.

Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women

Affiliations

Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women

Sara Sedano-Balbás et al. J Pregnancy. 2011.

Abstract

The combination of thrombophilia and pregnancy increases the risk of thrombosis and the potential for adverse outcomes during pregnancy. The most significant common inherited risk factor for thrombophilia is activated protein C resistance (APCR), a poor anticoagulant response of APC in haemostasis, which is mainly caused by an inherited single-nucleotide polymorphism (SNP), factor V G1691A (FV Leiden) (FVL), referred as inherited APCR. Changes in the levels of coagulation factors: FV, FVIII, and FIX, and anticoagulant factors: protein S (PS) and protein C (PC) can alter APC function causing acquired APCR. Prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T are prothrombotic SNPs which in association with APCR can also increase the risk of thrombosis amongst Caucasians. In this study, a correlation between an acquired APCR phenotype and increased levels of factors V, VIII, and IX was demonstrated. Thrombophilic mutations amongst our acquired APCR pregnant women cohort are relatively common but do not appear to exert a severe undue adverse effect on pregnancy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Graph comparing FV levels in differing groups within the study, (b) graph comparing FVIII levels in differing groups within the study, and (c) graph comparing F IX levels in differing groups within the study.

Similar articles

Cited by

References

    1. Gwyneth L, editor. Reports on Public Health and Medical Subjects 1994–1996. London, UK: Department of Health United Kingdom; 1998. Report on confidential enquiries into maternal deaths.
    1. Knijff SCM, editor. Summary of Contraindications to Oral Contraceptives. New York, NY, USA: Parthenon Publishing Group; 2000.
    1. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 2001;86:395–403. - PubMed
    1. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor V(R506Q) Journal of Biological Chemistry. 1995;270(8):4053–4057. - PubMed
    1. Axelsson F, Rosen S. APC Resistance. Chromogenix AB; (Product Monograph 1997). version 2.1 1997.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources